Answers are grounded in this paper and cite their sources.
CD22-targeted chimeric antigen receptor (CD22-CAR) T cells have been proven to be effective in treating patients with B acute lymphoblastic leukemia (B-ALL) who were unsuitable to receive CD19-CAR T cell therapy 1 , 2 , 3 . However, a considerable proportion of patients still relapsed after CD22-CAR T cell therapy 3 , 4 , with diminished or decreased levels of CD22 expression on blasts. For patients who had not completely lost CD22 expression on blasts, CD22-CAR T cell re-treatment may apply as a salvage regimen. But unfortunately, in a previous trial on a humanized CD22-CAR (termed CD22-CAR YK002 ) T cell therapy, a second CD22-CAR YK002 infusion produced no or suboptimal anti-leukemia response and CAR T cell expansion (Table S1 and Fig. S1 ). Because the immunogenicity of humanized antibodies or CARs has been suggested in previous studies 5 , 6 , 7 , 8 , the poor effect of the second CD22-CAR YK002 infusion might be due to the patient’s immune response against CD22-CAR YK002 transgene. On the other hand, CD22 downregulation might also represent a mechanism of resistance to a second CAR T-cell therapy 3 . Therefore, a new CD22-CAR with no cross immunogenicity with CD22-CAR YK002 , and with strong activity against CD22 low cells, may be effective for the second treatment of patients who failed from previous CD22-CAR YK002 T cell therapy. Furthermore, since the immunogenicity of full-human antibodies tends to be reduced compared with humanized or chimeric constructs 9 , 10 , 11 , the usage of fully human-derived CAR constructs might be a better strategy, which can further lower the risk of developing immune responses against the secondarily infused CAR T cells.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: